RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ZAMAGNI C
Collezione AO Ordine Mauriziano

Items : 8

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2.

2024
AO Ordine Mauriziano

Colombo N; Biagioli E; Harano K; Galli F; Hudson E; Antill Y; Choi CH; Rabaglio M; Marmé F; Marth C; Parma G; Fariñas-Madrid L; Nishio S; Allan K; Lee YC; Piovano E; Pardo B; Nakagawa S; McQueen J; Zamagni C; Manso L; Takehara K; Tasca G; Ferrero A; Tognon G; Lissoni AA; Petrella M; Laudani ME; Rulli E; et alii...

In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study. in Journal of clinical pathology / J Clin Pathol. 2024 Jun 19;77(7):478-485. doi: 10.1136/jcp-2023-208852.

2024
AO Ordine Mauriziano

Pepe F; Guerini-Rocco E; Fassan M; Fusco N; Vacirca D; Ranghiero A; Venetis K; Rappa A; Taormina SV; Russo G; Rebellato E; Munari G; Moreno-Manuel A; De Angelis C; Zamagni C; Valabrega G; Malapelle U; Troncone G; Barberis M; Iaccarino A;

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. in Cancers / Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041.

2023
AO Ordine Mauriziano

Turinetto M; Ricotti A; Marchetti C; Pisano C; Zamagni C; Cassani C; Malaguti P; Baldoni A; Scollo P; Scandurra G; Parisi A; Artioli G; Palaia I; Vertechy L; Bergamini A; Picardo E; Tuninetti V; Scotto G; Scambia G; Pignata S; Valabrega G;

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023.

2023
AO Ordine Mauriziano

Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Loizzi V; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G; Arezzo F; Giannone G; Castaldo D; Scotto G; Tuninetti V; Turinetto M; Bartoletti M; Mammoliti S; et alii...

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2023 Aug 7;13:1232476. doi: 10.3389/fonc.2023.1232476. eCollection 2023.

2023
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors. in Frontiers in oncology / Front Oncol. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291. eCollection 2023.

2023
AO Ordine Mauriziano

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. in Frontiers in oncology / Front Oncol. 2022 Sep 21;12:979519. doi: 10.3389/fonc.2022.979519. eCollection 2022.

2022
AO Ordine Mauriziano

Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N;

Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey. in Frontiers in oncology / Front Oncol. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008. eCollection 2022.

2022
AO Ordine Mauriziano

Giannone G; Castaldo D; Tuninetti V; Scotto G; Turinetto M; Valsecchi AA; Bartoletti M; Mammoliti S; Artioli G; Mangili G; Salutari V; Lorusso D; Cormio G; Zamagni C; Savarese A; Di Maio M; Ronzino G; Pisano C; Pignata S; Valabrega G;